There are 2789 resources available
Melanoma and other skin tumours
Presenter: Omid Hamid
Session: Expert selection 2
Resources:
Slides
Webcast
Introduction by the Chair
Presenter: Jordi Rodon
Session: Keynote lecture: Drug development: How can academia and industry work together
Resources:
Slides
Webcast
Drug development: How can academia and industry work together
Presenter: Jean-Charles Soria
Session: Keynote lecture: Drug development: How can academia and industry work together
Resources:
Slides
Webcast
LBA16 - KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Presenter: Hope Rugo
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1757O - Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
Presenter: Alexander Shoushtari
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
1758O - Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
Presenter: Kaysia Ludford
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
1124O - Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides
Presenter: Ingrid Garberis
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Presenter: Gabriel Hortobagyi
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA28 - STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)
Presenter: Janet Brown
Session: Proffered Paper session - Genitourinary tumours, non-prostate 2
Resources:
Abstract
Slides
Webcast
LBA29 - Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Presenter: Naveen Vasudev
Session: Proffered Paper session - Genitourinary tumours, non-prostate 2
Resources:
Abstract
Slides
Webcast